{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:47:18Z","timestamp":1772160438206,"version":"3.50.1"},"reference-count":64,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T00:00:00Z","timestamp":1340150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The incidence of oesophageal adenocarcinoma (\n                      <jats:styled-content style=\"fixed-case\">OAC<\/jats:styled-content>\n                      ) has risen dramatically in recent decades, and its prognosis remains extremely poor. There is emerging evidence that statins may prevent\n                      <jats:styled-content style=\"fixed-case\">OAC<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>\n                      To systematically review both the experimental and epidemiological evidence to determine whether statins reduce the risk of developing\n                      <jats:styled-content style=\"fixed-case\">OAC<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Relevant laboratory and epidemiological studies were identified by systematically searching the\n                      <jats:styled-content style=\"fixed-case\">PUBMED<\/jats:styled-content>\n                      and\n                      <jats:styled-content style=\"fixed-case\">EMBASE<\/jats:styled-content>\n                      electronic databases for data on statins and oesophageal cancer (\n                      <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>\n                      ). The evidence was assessed according to the nine\n                      <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\n                      radford\n                      <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>\n                      ill criteria (\n                      <jats:styled-content style=\"fixed-case\">BHC<\/jats:styled-content>\n                      ) of causality. Pooled effect sizes (\n                      <jats:styled-content style=\"fixed-case\">ES<\/jats:styled-content>\n                      ) were calculated for the risk of\n                      <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>\n                      with prior statin use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Many of the\n                      <jats:styled-content style=\"fixed-case\">BHC<\/jats:styled-content>\n                      were supported including: \u2018plausible biological mechanisms\u2019, \u2018coherence\u2019, \u2018strong associations\u2019, \u2018consistency\u2019, \u2018biological gradient\u2019, \u2018analogy\u2019 and \u2018temporality\u2019. Three experimental studies reported that statins inhibited proliferation, induced apoptosis and may limit metastatic potential in\n                      <jats:styled-content style=\"fixed-case\">OAC<\/jats:styled-content>\n                      cell lines. Fixed effects meta\u2010analysis of two prospective studies in Barrett's oesophagus cohorts, involving 1382 participants, showed an\n                      <jats:styled-content style=\"fixed-case\">ES<\/jats:styled-content>\n                      of 0.53 (95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      \u00a0=\u00a00.36\u20130.78,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00%) for risk of\n                      <jats:styled-content style=\"fixed-case\">OAC<\/jats:styled-content>\n                      with prior statin use. Meta\u2010analysis of three prospective studies in general population cohorts, involving 35\u00a0214 participants, showed an\n                      <jats:styled-content style=\"fixed-case\">ES<\/jats:styled-content>\n                      of 0.86 (95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      \u00a0=\u00a00.78\u20130.94,\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\u00a00.001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00%) for risk of\n                      <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>\n                      with prior statin use. The most important criterion, \u2018experiment\u2019, is as yet unfulfilled as to date there are no clinical trials which investigate this hypothesis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      There is some evidence that statins may protect against the development of\n                      <jats:styled-content style=\"fixed-case\">OAC<\/jats:styled-content>\n                      , although to be conclusive, data from randomised clinical trials are required.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1365-2036.2012.05194.x","type":"journal-article","created":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T09:29:01Z","timestamp":1340270941000},"page":"301-311","source":"Crossref","is-referenced-by-count":25,"title":["Systematic review: potential preventive effects of statins against oesophageal adenocarcinoma"],"prefix":"10.1111","volume":"36","author":[{"given":"L.","family":"Alexandre","sequence":"first","affiliation":[{"name":"Norwich Medical School University of East Anglia Norwich UK"},{"name":"Norfolk and Norwich University Hospital NHS Foundation Trust Norwich UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Clark","sequence":"additional","affiliation":[{"name":"Norwich Medical School University of East Anglia Norwich UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Cheong","sequence":"additional","affiliation":[{"name":"Norfolk and Norwich University Hospital NHS Foundation Trust Norwich UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P. N.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Norfolk and Norwich University Hospital NHS Foundation Trust Norwich UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"Hart","sequence":"additional","affiliation":[{"name":"Norwich Medical School University of East Anglia Norwich UK"},{"name":"Norfolk and Norwich University Hospital NHS Foundation Trust Norwich UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,6,20]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20107"},{"key":"e_1_2_5_3_1","first-page":"669","article-title":"Trends in incidence of oesophageal and stomach cancer subtypes in Europe","volume":"22","author":"Steevens J","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605246"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03460100089030"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02191.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn211"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860701403046"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11228"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2083"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(94)90057-4"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.04.010"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198608073150605"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903183401101"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0804684"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.131375"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.12.009"},{"key":"e_1_2_5_19_1","first-page":"85","article-title":"Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma","volume":"4","author":"Vaughan TL","year":"1995","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000097947"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-3-200008010-00007"},{"key":"e_1_2_5_22_1","first-page":"749","article-title":"Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux","volume":"7","author":"Vaughan TL","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.05.022"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2011.01285.x"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604880"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01773.x"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2011.08.004"},{"issue":"3","key":"e_1_2_5_28_1","first-page":"141","article-title":"Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX\u20102 and apoptosis\u2010related proteins","volume":"58","author":"Konturek PC","year":"2007","journal-title":"J Physiol Pharmacol"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2197"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601566"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.02.045"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-409"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.08.036"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2011.239301.72"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.06.001"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1507"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/003591576505800503"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2221"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/343425a0"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.65.070196.001325"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23593"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M610350200"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.08.021"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0261fje"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2004.09.028"},{"key":"e_1_2_5_46_1","first-page":"1167","article-title":"Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria\u2010operated pathway","volume":"48","author":"Zhang W","year":"2010","journal-title":"Indian J Exp Biol"},{"key":"e_1_2_5_47_1","first-page":"4885","article-title":"Inhibition of epidermal growth factor\u2010induced RhoA translocation and invasion of human pancreatic cancer cells by 3\u2010hydroxy\u20103\u2010methylglutaryl\u2010coenzyme a reductase inhibitors","volume":"61","author":"Kusama T","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_5_48_1","first-page":"717","article-title":"Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild\u2010type K\u2010ras oncogene but has different effects on protein phosphorylation and induction of apoptosis","volume":"12","author":"Muller C","year":"1998","journal-title":"Int J Oncol"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.06.016"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202792"},{"key":"e_1_2_5_51_1","first-page":"2761","article-title":"Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells","volume":"20","author":"Bouterfa HL","year":"2000","journal-title":"Anticancer Res"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-0098"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgh201"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22895"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182049d8b"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401873"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgi036"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2007.01.016"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1393"},{"key":"e_1_2_5_60_1","first-page":"553","article-title":"Immunoreactivity of ICAM\u20101 in human tumors, metastases and normal tissues","volume":"2","author":"Hayes SH","year":"2009","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-004-3485-7"},{"key":"e_1_2_5_62_1","volume-title":"National Oesophago\u2010Gastric Cancer Audit","author":"Palser T","year":"2009"},{"key":"e_1_2_5_63_1","first-page":"261","article-title":"Pleiotropic effects of the HMG\u2010CoA reductase inhibitors","volume":"4","author":"Mihos CG","year":"2011","journal-title":"Int J Gen Med"},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740331003662620"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03582.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2012.05194.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2012.05194.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T08:02:40Z","timestamp":1700553760000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2012.05194.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,20]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1365-2036.2012.05194.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05194.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717949502.793455342","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717949502.793454702","asserted-by":"object"}]},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,20]]}}}